SCHEDULE 13G: Red Peony Association 1st Discloses 5.7% Stake in Liminatus Pharma, Inc.
Beneficial Ownership Report
Red Peony Association 1st has reported a beneficial ownership of 5.7% in Liminatus Pharma, Inc., holding 1,470,000 shares of common stock.
Summary
- Red Peony Association 1st has filed a Schedule 13G, indicating beneficial ownership in Liminatus Pharma, Inc.
- The reporting person, Red Peony Association 1st, beneficially owns 1,470,000 shares of Liminatus Pharma, Inc.'s common stock.
- This ownership represents 5.7% of the total outstanding common stock of Liminatus Pharma, Inc.
- The percentage is calculated based on 26,014,633 shares of common stock outstanding following the consummation of a business combination on April 30, 2025.
- Red Peony Association 1st holds sole voting power and sole dispositive power over all 1,470,000 shares.
Sentiment
Score: 7
Explanation: The filing indicates a significant beneficial ownership stake acquired by Red Peony Association 1st, which can be interpreted as a positive signal of investor confidence in Liminatus Pharma, Inc. following its business combination.
Positives
- A significant institutional investor, Red Peony Association 1st, has acquired a 5.7% stake in Liminatus Pharma, Inc., which may signal confidence in the company's prospects following its recent business combination.
Future Outlook
No specific forward-looking statements or guidance are provided in this beneficial ownership report.
Industry Context
The acquisition of a significant stake by an institutional investor like Red Peony Association 1st in a pharmaceutical company such as Liminatus Pharma, Inc., especially after a business combination, can be viewed as a positive indicator within the biotech and pharmaceutical industry, suggesting potential growth or strategic value.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may enhance market confidence and potentially stabilize or positively influence the share price.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date of event which required the filing of this statement, coinciding with the consummation of the Business Combination. |
| 06/26/2025 | Date of signature on the Schedule 13G filing by Red Peony Association 1st. |
Recommendation
holdKeywords
Liminatus Pharma, Red Peony Association, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, business combination
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.